Related Experiment Videos
[Severe neonatal hyperthyroidism which reveals a maternal Graves' disease]
B Guérin1, V Vautier, V Boin-Gay
1Service de pédiatrie et réanimation pédiatrique, centre hospitalier de Pau, 4, boulevard Hauterive 64046 Pau.
Annales D'Endocrinologie
|July 13, 2004
Summary
Graves' disease in pregnancy can cause fetal hyperthyroidism due to maternal antibodies stimulating the fetal thyroid. Neonatal thyrotoxicosis typically resolves as maternal antibodies clear, but requires careful diagnosis and monitoring.
Area of Science:
- Endocrinology
- Obstetrics
- Neonatology
Context:
- Graves' disease complicates approximately 0.2% of pregnancies.
- Maternal thyroid-stimulating immunoglobulins (TSI) cross the placenta, potentially affecting fetal thyroid function.
- Neonatal thyrotoxicosis presents with specific clinical signs and requires accurate diagnosis.
Purpose:
- To summarize the pathophysiology, diagnosis, and management of Graves' disease in pregnancy and its impact on the neonate.
- To highlight the role of maternal antibodies and TSH receptor stimulation in fetal hyperthyroidism.
- To present a case of severe neonatal hyperthyroidism leading to maternal Graves' disease diagnosis.
Summary:
- Maternal Graves' disease can lead to neonatal hyperthyroidism via transplacental transfer of TSI, which stimulate the fetal TSH receptor.
- Clinical manifestations in neonates include tachycardia, goiter, and poor weight gain; diagnosis relies on T3, T4, TSH, and TSI levels.
- Neonatal thyrotoxicosis is usually transient, resolving within months as maternal antibodies clear, though rare familial non-autoimmune hyperthyroidism exists.
Impact:
- Provides a comprehensive overview for clinicians managing pregnant patients with Graves' disease and their neonates.
- Emphasizes the importance of monitoring TSI levels for therapeutic guidance and assessing recovery.
- Contributes to understanding the spectrum of neonatal thyroid dysfunction and its association with maternal autoimmune conditions.